Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multi-omics analysis of primary glioblastoma cell-lines shows recapitulation of pivotal molecular features of parental tumors

ABSTRACT: Glioblastoma (GBM) is the deadliest primary brain cancer in adults. Emerging innovative therapies hold promise for personalized cancer treatment. Improving therapeutic options depends on research relying on relevant preclinical models. In this line we have established in the setting of the GlioTeX project (GBM and experimental therapeutics), a GBM-patient derived cell line library (GBM-PDCL). Multi-OMIC approach was used to determine the molecular landscape of PDCL and the extent to which they represent GBM tumors.

PROVIDER: EGAS00001001871 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.

Rosenberg Shai S Verreault Maïté M Schmitt Charlotte C Guegan Justine J Guehennec Jeremy J Levasseur Camille C Marie Yannick Y Bielle Franck F Mokhtari Karima K Hoang-Xuan Khê K Ligon Keith K Sanson Marc M Delattre Jean-Yves JY Idbaih Ahmed A

Neuro-oncology 20170201 2

<h4>Background</h4>Glioblastoma (GBM) is the deadliest primary brain cancer in adults. Emerging innovative therapies hold promise for personalized cancer treatment. Improving therapeutic options depends on research relying on relevant preclinical models. In this line we have established in the setting of the GlioTex project (GBM and Experimental Therapeutics) a GBM patient-derived cell line (GBM-PDCL) library. A multi-omic approach was used to determine the molecular landscape of PDCL and the ex ...[more]

PMID: 27571888

Similar Datasets

SUV39H1 Maintains Cancer Stem Cells in Glioblastoma [ATAC-seq]

Project description:Glioblastoma (GBM) is the deadliest brain cancer, driven in part by GBM stem cells (GSCs) that contribute to therapeutic resistance and tumor recurrence. Effective targeting and elimination of GSCs hold promise for preventing GBM recurrence and achieving potential cures. In this study, we explored the role of the epigenetic regulator SUV39H1 in GSC maintenance and GBM progression. We observed that SUV39H1 is upregulated in GBM samples compared to normal brain tissues. Single-cell RNA-seq data indicated that SUV39H1 is preferentially expressed in GSCs relative to non-stem GBM cells, possibly due to super-enhancer-mediated transcriptional activation. Knockdown of SUV39H1 in patient-derived GSCs impaired their proliferation and stemness. RNA-seq analysis revealed that SUV39H1 regulates G2/M cell cycle progression, stem cell maintenance, and cell death pathways in GSCs. Integrated ATAC-seq (assay for transposase-accessible chromatin followed by sequencing) and RNA-seq analyses demonstrated that targeting SUV39H1 altered chromatin accessibility in key genes associated with these pathways. Treatment with chaetocin, a SUV39H1 inhibitor, mimicked the effects of SUV39H1 knockdown in GSCs and sensitized them to the GBM chemotherapy drug temozolomide (TMZ). In vivo studies using an intracranial patient-derived xenograft model showed that targeting SUV39H1 inhibited GSC-driven tumor formation in mice. Our findings identify SUV39H1 as a critical regulator of GSC maintenance and suggest that targeting SUV39H1 could disrupt GSCs and enhance the efficacy of existing chemotherapy, offering a promising strategy for improving GBM treatment outcomes.

2024-11-06 | GSE273013 | GEO

SUV39H1 Maintains Cancer Stem Cells in Glioblastoma [RNA-seq]

2024-11-06 | GSE273012 | GEO

Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.

Project description: Not available

| S-EPMC5463853 | biostudies-literature

RNA-seq of four glioblastoma (GBM) cell lines treated with irradiation, PARP7i, diABZI alone or in combination with irradiation

Project description:Glioblastoma (GBM) is the deadliest type of brain cancer, exhibiting resistance not only to traditional treatments like radiation and chemotherapy but also to modern immunotherapy. GBM is classified as an immunologically cold tumor with an immunosuppressive microenvironment. Radio- and chemotherapy have been shown to alter the tumor microenvironment and trigger an anti-tumor immune response in various cancers, including breast, lung, and colorectal cancer, via the cGAS/STING and type I interferon (IFN-I) pathway. Additionally, STING agonists and inhibitors of DNA damage response and cell cycle checkpoints, which promote the accumulation of immunostimulatory cytoplasmic dsDNA, have been found to enhance the effects of radiation. Here we examined the immunogenic response of four different GBM cell lines (U251, T98G, GB-1, KALS-1) exposed to hypofractionated X-ray radiation (3x8 Gy) in combination with a STING agonist or with inhibitors targeting immune signaling (PARP7). We performed RNA-seq analysis of all four GBM cell lines treated with 3x8 Gy, PARP7i, diABZI alone or in combination with 3x8 Gy.

2026-01-01 | E-MTAB-14858 | biostudies-arrayexpress

Multi-omics analysis of primary glioblastoma cell-lines shows recapitulation of pivotal molecular features of parental tumors

Project description:The goal of the study was to describe and compare the genomic landscape of Glioblastoma parental tumors and PAIRED patient derived cell lines(PDCLs). This approach enables to examine and estimate the extent to which PDCLs recapitulates the genome landscape of parental tumors - which is important for experimental model validation. In addition the consistent differences between tumors and PDCL can be evaluated in order to identify the model's weak points. In the enclosed experiment, nine pairs of Glioblastoma tumors and paired PDCL (18 samples) were analyzed for transcriptome. Complementary data on copy-number variation have been deposited at ArrayExpress under accession number E-MTAB-4804 (http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-4804).

2016-11-01 | E-MTAB-4803 | biostudies-arrayexpress

Multi-omics analysis of primary glioblastoma cell-lines shows recapitulation of pivotal molecular features of parental tumors

Project description:The goal of the study was to describe and compare the genomic landscape of Glioblastoma parental tumors and PAIRED patient derived cell lines(PDCLs). This approach enables to examine and estimate the extent to which PDCLs recapitulates the genome landscape of parental tumors - which is important for experimental model validation. In addition the consistent differences between tumors and PDCL can be evaluated in order to identify the model's weak points. In the enclosed data set, copy number variation analysis for 10 pairs of Glioblastoma tumors and their paired PDCLs are given(20 samples). Complementary data on transcriptome have been deposited at ArrayExpress under accession number E-MTAB-4803 (http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-4803).

2016-11-01 | E-MTAB-4804 | biostudies-arrayexpress

SEVERE CONSEQUENCES OF A HIGH-LIPID DIET INCLUDE HYDROGEN SULFIDE DYSFUNCTION AND DISEASE AGGRESSION IN GLIOBLASTOMA

Project description:Glioblastoma (GBM) remains among the deadliest of human malignancies, and the emergence of the cancer stem cell (CSC) phenotype represents a major challenge to durable treatment response. Because the environmental and lifestyle factors that impact CSC populations are not clear, we sought to understand the consequences of diet on CSC enrichment. We evaluated disease progression in mice fed an obesity-inducing high-fat diet (HFD) versus a low-fat, control diet. HFD resulted in hyper-aggressive disease accompanied by CSC enrichment and shortened survival. HFD drove intracerebral accumulation of saturated fats, which inhibited the production of the cysteine metabolite and gasotransmitter, hydrogen sulfide (H2S). H2S functions principally through protein S-sulfhydration and regulates multiple programs including bioenergetics and metabolism. Inhibition of H2S increased proliferation and chemotherapy resistance, whereas treatment with H2S donors led to death of cultured GBM cells and stasis of GBM tumors in vivo. GBM specimens present an overall reduction in protein S-sulfhydration, primarily associated with proteins regulating cellular metabolism. These findings provide new evidence that diet modifiable H2S signaling serves to suppress GBM by restricting metabolic fitness, while its loss triggers CSC enrichment and disease acceleration. Interventions augmenting H2S bioavailability concurrent with GBM standard of care may improve outcomes for GBM patients.

2021-05-25 | PXD023685 | Pride

SEVERE CONSEQUENCES OF A HIGH-LIPID DIET INCLUDE HYDROGEN SULFIDE DYSFUNCTION AND DISEASE AGGRESSION IN GLIOBLASTOMA

2021-05-25 | PXD025902 | Pride

Abemaciclib reduces glioblastoma stemness by targeting the GSK3b-mediated transcriptional regulation of CD44 and TCF7L2.

Project description:Glioblastoma multiforme (GBM) is the most common and deadliest glioma, originating from astrocytic progenitors or stem cells and affecting individuals of all ages. Current treatments include surgery, radiation therapy, chemotherapy, and combinations of these modalities. Temozolomide, the first-line chemotherapy for GBM, improves survival when combined with radiation but has limited success due to the tumor's inherent resistance to therapies. Cancer stem cells (CSCs), which exhibit self-renewal and differentiation capabilities, contribute to therapeutic resistance, making them a promising target for GBM therapy. Abemaciclib, a CDK4/6 inhibitor, effectively reduces tumor growth and sphere formation in GBM, although its exact mechanism remains unclear. Our data revealed that Abemaciclib significantly inhibited tumor sphere formation in U87MG and KNS42 cells by downregulating epithelial-mesenchymal transition (EMT)-associated genes, including CD44 and TCF7L2. Notably, silencing CD44 and TCF7L2 also led to a marked reduction in sphere formation. Phospho-kinase array analysis revealed that Abemaciclib reduces pGSK3β and pCREB in sphere cells. Western blotting confirmed that Abemaciclib diminishes pGSK3β-Y216 in parental cells, suggesting reduced kinase activity. Pharmacological inhibition of GSK3β also decreased CD44 and TCF7L2 expression. In an orthotopic animal model, Abemaciclib inhibited tumor formation, with reduced levels of pRB, pGSK3β, Ki67, and CD44 confirmed by immunohistochemistry. Analysis of TCGA and CGGA datasets showed that the mesenchymal GBM subtype (MES-GBM), associated with poor prognosis, has higher EMT gene expression. Treatment of MES-like LN229 cells with Abemaciclib decreased EMT-related genes. These findings suggest that Abemaciclib disrupts GSK3β-mediated EMT pathways, impairing CSC self-renewal and offering a potential therapeutic strategy for GBM.

2025-03-12 | GSE290174 | GEO

MCRS1 sensitizes pancreatic cancer to T cell immunity [Tumor]

Project description:Pancreatic cancer is one of the deadliest cancers in humans and is yet refractory to immunotherapy. Identifying factors that can sensitize pancreatic cancer to immune cells may thus hold the key to improving immunotherapy efficacy. Herein, by pooled CRISPR activation screening, we find that the transcriptional regulator Mcrs1 (Microspherule protein 1) is pivotal to the immune sensitivity of pancreatic cancer cells, with elevated Mcrs1 expression inducing enhanced immune responses and tumor suppression in mice.

2024-10-14 | GSE239364 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data